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Case presentation
A 42-year-old white man was admitted to the hospital 5 years after his
second renal transplant because of angina and congestive heart failure in
association with an elevation of his serum creatinine to 3.2 mg/dl from its
baseline of 1.9 mg/dl. The patient had had poorly controlled hypertension
for many years. He had noted increasing dyspnea on exertion for 2 weeks
prior to admission, with several episodes of exertional chest pain. He had
coronaiy artery disease, with a 75% stenosis of the left coronary artery,
along with severe left-ventricular hypertrophy, which had been demon-
strated on cardiac catheterization in 1988.
The patient had received his first renal transplant from his brother in
1984 after developing end-stage renal disease due to membranous gb-
merulopathy. Maintenance immunosuppression consisted mainly of pred-
nisone and azathioprine; the allograft failed in 2 years after several acute
rejection episodes. His current cadaveric allograft, which was a zero HLA
match from a 27-year-old white man, was placed in 1988. After an initial
period of oliguria requiring dialysis, and antilymphocyte globulin, 20
mg/day for 10 days, cycbosporine A was started at a dose of 12 mg/kg and
tapered to maintenance levels of 100—200 mg/mI (whole blood/parent
compound). Prednisone was tapered to a dose of 10 mg/day by one year
after transplantation. His initial course was further complicated by an
episode of steroid-responsive rejection at 2 weeks; cytomegalovirus esoph-
agitis at one month; a community-acquired pneumonia at 3 months; and
pseudomembranous colitis at 4 months. His hypertension worsened over
the next 4 years, with repeated measurements in the outpatient setting of
170—220/100—120 mm Hg. Several medications were prescribed to control
his blood pressure, but the patient did not take them consistently,
frequently because of their expense. Because of repeatedly high blood
cyclosporine levels and pharmacokinetic testing that demonstrated de-
layed metabolism, cyclosporine dosing was switched to every-other-day in
1992. Serum cholesterol levels were persistently high (total cholesterol,
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250—300 mg) and he gained 60 lbs. In 1992, 4 years post transplant, he
developed 2+ to 3+ proteinuria, which was quantitated at 3.9 g protein/
day.
On physical examination, his blood pressure was 160/110 mm Hg.
Basilar rales and a loud S4 gallop were present. He had 1 + pedal edema,
and his renal allograft was palpable and nontender. A chest radiograph
revealed congestive heart failure. The serum BUN and creatinine levels
were 38 mg/dl and 3.2 mg/dl respectively (serum creatinine concentration
had been 1.9 mg/dl 4 months previously). The cholesterol level was 286
mg/dl. The hematocrit was 49% with a white blood cell count of
11,800/mm3. Urinalysis revealed 3+ protein with 2—5 red blood cells/mm3
and 0—1 white blood cells/mm3. Repeat cardiac catheterization revealed
persistent LVH but no change in his coronary artery lesions since 1988.
The serum creatinine concentration ranged between 3.2 mg/dl and 3.6
mg/dt. A Doppler ultrasound of the renal allograft revealed normal
systolic and diastolic flow patterns. Cyclosporine blood levels were not
elevated.
A renal biopsy (Fig. 1) revealed extensive interstitial fibrosis with
minimal interstitial edema, lymphocytic infiltrate, or tubulitis. A dramatic
degree of hyaline thickening of blood vessel walls and several scarred
glomeruli were present; these changes are consistent with chronic rejec-
tion, chronic hypertension, and/or cyclosporine toxicity. Blood pressure
control was achieved with labetolol and minoxidil, and the patient was
discharged. He continues to have poor but stable renal function (ereati-
nine, 2.9 mg/dl) and inconsistently controlled hypertension (several out-
patient readings still 160/110 mm Hg).
Discussion
DR. MARGARET JOHNSON BIA (Director, Transplant Nephrology,
and Professor of Medicine, Yale University School of Medicine, New
Haven, Connecticut): This case, the predominant feature of which
is a poorly functioning renal allograft 5 years post transplant,
demonstrates a very common and unfortunate scenario. Despite
continued improvement in one-year graft survival for cadaveric
renal transplants, long-term graft survival—as measured by al-
lograft half-life after the first year—has changed little in the past
two decades (Fig. 2) [1—3]. Data from both the UNOS (United
Network for Organ Sharing) and the UCLA Transplant Registry
files demonstrate that one-year graft survival rates of 80% to 85%
can now be expected for recipients of first cadaveric grafts [1, 3].
This figure drops by 6% to 8% for recipients of second trans-
plants, as in today's patient [4]. However, more than 50% of the
allografts that do survive for one year fail before 10 years.
Although long-term graft survival varies markedly among trans-
plant centers [5], the average half-life of a cadaveric kidney
remains 7.8 years, even in the most recently reviewed time period
(1985—1990) [1, 3, 5].
Reasons for renal allograft loss after the first year appear in
Table 1. Chronic rejection remains the leading cause [6—8].
Patient death from cardiovascular or infectious causes is another
major reason for transplant failure over time, especially in older
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Fig. 1. Renal allog,raft biopsy specimen demonstrating severe narrowing and hyalinization of blood vessel (arrow), scierosed glomeml4 tubular atrophy, and
extensive interstitial fibrosis.
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demonstrating continued improvement in one-year
renal allograft survival (top line) without
concomitant in allograft half-life after the first
year (bottom line) [1]. Numbers on the vertical
above each year represent number of
transplants registered that year.
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Table 1. Causes of renal allograft loss after one yea?recipients and those with diabetes mellitus. Noncompliance con-
tributes to graft loss in as many as 30% of cases in some series [6,
9] and undoubtedly played a role in this patient's course. Other,
less common, reasons for graft loss include acute rejection,
recurrence of disease, urinary tract obstruction, pyelonephritis,
and renal artery stenosis. Today's patient had no evidence for
recurrence of membranous glomerulopathy in the transplant
biopsy specimen.
The pathologic changes observed in this patient's biopsy have
been generally attributed to an allogeneic immune response
referred to as chronic rejection. Clinical presentation of chronic
rejection is characterized by an otherwise unexplained progressive
loss of allograft function in association with hypertension and
proteinuria [10—12]. Histologically, vascular lesions with narrow-
ing of the arteries secondary to myointimal proliferation are most
prominent, along with resultant glomerulosclerosis, tubular atro-
phy, and interstitial fibrosis [10—141. Evidence supporting an
immune mechanism for this process includes the higher frequency
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Table 2. Potential nonimmunologic causes of renal allograft injury
Hemodynamic factors (glomerular hyperfiltration/hypertension)
Systemic hypertension
Renal ischemic injury
Drug toxicity
Hyperlipidemia
that chronic rejection is associated with lower blood levels of
immunosuppressive drugs [19, 20]. The similar occurrence of
obliterative fibrosis in hollow structures of other organ allografts,
such as heart, liver, and lung, also suggests a common immuno-
logic mechanism [11, 21—231.
Immunologic factors certainly play a major role in the devel-
opment of chronic rejection, but graft failure from this process has
remained refractory to immunosuppressive treatment, even with
the use of more potent agents such as cyclosporine [1, 2].
Furthermore, many of the histopathologic features seen in this
process, such as arteriolar narrowing, glomerulosclerosis, and
interstitial fibrosis, also are observed in renal disease from other
causes. These data, coupled with the knowledge that nonimmu-
nologic factors increase the likelihood of progression toward total
renal failure in native kidneys [24], have led to the recent
suggestion that such factors also might play an important role in
renal allograft damage [21, 25, 26]. Indeed, in the recently
standardized Banif classification of transplant pathology [13],
chronic rejection is referred to as "chronic allograft nephropathy"
in recognition of the fact that several explanations might exist for
the observed pathologic lesions. Table 2 lists potential nonimmu-
nologic causes of renal allograft injury. I will review the available
evidence supporting the significance of these factors and their
potential contribution to renal allograft damage in today's patient.
But let me emphasize at the outset that investigations into the
relative importance of these factors in allograft injury have only
just begun.
Hemodynamic factors. Hemodynamic factors such as glomerular
hyperfiltration and hypertension contribute to progression of
renal damage in many animal models of renal injury [24, 27—301.
These adaptive changes can lead to glomerular sclerosis and
progressive loss of renal function, especially if they are associated
with glomerular hypertrophy [29]. A 50% reduction in renal mass
appears to be safe and not associated with long-term sequelae.
Microalbuminuria, demonstrated in as many as one-third of renal
donors, suggests the presence of hyperfiltration [311, but renal
function has been well preserved for the 10 to 20 years during
which these patients have been followed [31, 32]. In contrast, if
renal mass is reduced by more than 50%, progressive loss of renal
function may ensue [331, although survival with stable serum
creatinine levels for 20 to 30 years has been documented in
patients with only a remnant kidney [34]. Glomerular capillary
pressure increases in experimental models of chronic allograft
rejection [35, 361. The question just now starting to be addressed
in experimental and clinical studies is whether hyperfiltration
contributes significantly to renal allograft injury.
Even more intriguing is the question of whether inadequate
"nephron dosing" at the time of transplantation plays a role in this
process. That is, does mismatching the donor nephron supply with
the metabolic demands of the recipient lead to allograft injury?
Several lines of evidence support this provocative hypothesis [25].
For example, long-term renal allograft survival of kidneys from
Table 3. Clinical and laboratory comparisons in patients with stable
allograft function'
Male Female
Albumin excretion (mg/day) 112 131 18 16"
Creatinine clearance (mI/mm) 87 23 76 18
Serum creatinine (mg!dl) 1.4 0.4 1.0 0.2c
Weight (kg) 84 16 64 18C
Protein intake (g/day) 90 18 75 14C
a Data from Ref. 46
bp 0.0062
P < 0.005
older donors (>50 years old) is inferior [3, 22, 37] with a half-life
40% lower than in younger donors [3]. This decreased viability
might be related to an increased susceptibility of older kidneys to
ischemic damage and rejection [38]. In a recent study of trans-
plant recipients with stable renal function 2 years post transplant,
the degree of glomerular sclerosis on biopsy correlated positively
with donor age [39]. This correlation suggested that age-related
glomerulosclerosis also contributes to the decreased survival of
these grafts. Kidneys from younger donors (5 years old) also
fare less well [37], in part because of technical problems in
harvesting and transplanting these small organs. But the increased
frequency of proteinuria and focal glomerulosclerosis in adult
recipients of kidneys from younger donors (6 years old [40])
suggests that other factors, such as hyperfiltration, also might play
a role in these cases.
The impact of inadequate nephron dosing also might account
for the observation that renal allograft survival is diminished in
obese renal transplant recipients [37, 41]. Again, technical diffi-
culties during surgery and difficulties with immunosuppressive
dosing might explain this phenomenon. However, two studies
recently demonstrated a positive relationship between long-term
graft survival and the ratio of either donor kidney weight/recipient
weight [42] or donor/recipient body surface area [43], suggesting
that inadequate nephron dosing also could be important. Exper-
imental data also have demonstrated that transplanted rats re-
ceiving a greater nephron dose (that is, one native kidney is left in
place) experience less glomerular hyperfiltration and renal al-
lograft damage than do rats with both native kidneys removed
[35]. These results further support the importance of nephron
dosing and its impact on long-term graft survival.
Registry data also demonstrate shortened long-term survival of
renal allografts from female donors transplanted to male recipi-
ents [3, 44]. No obvious immunologic reason explains this finding,
but it might be due to the smaller size and thus decreased nephron
number in female compared with male kidneys [451. We recently
presented results supporting this interpretation [46]. In our study,
we set out to determine the frequency of microalbuminuria
(defined as 30—300 mg of albumin/24 hr) in 53 renal transplant
recipients with stable graft function (creatinine clearance 50
mI/mm). All patients were 1 to 12 years post transplant. Mi-
croalbuminuria was present in 25 (47%) of these patients, 23 of
whom were male. We utilized stepwise multiple regression anal-
ysis to identify recipient factors associated with microalbuminuria.
We found that serum creatinine concentration and male gender
were important determinants of graft survival. As Table 3 shows,
urinary albumin excretion was higher in male versus female
recipients. As expected, weight, serum creatinine concentration,
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and protein intake also were higher in males. The frequency of
female-to-male donation pairs was significantly higher (P =
0.0097) in recipients with microalbuminuria (9/25) compared to
those without (2/28). The finding of microalbuminuria predomi-
nantly in male recipients, in whom weight and protein intake also
were higher, along with the higher frequency of microalbuminuria
in males receiving a female kidney, suggests that hyperfiltration
from inadequate nephron dosing might contribute to microalbu-
minuria in this select group of stable transplant patients. It is likely
that our patient received an adequate "nephron dose" initially,
since his donor was a 27-year-old male. However, neither the
weight of the donor nor of the donor kidney were recorded at the
time of transplantation, making it impossible to calculate a donor
kidney weight/recipient weight ratio [25, 42].
Systemic hypertension. Another factor that likely contributed to
renal allograft injury in today's patient is systemic hyperten-
sion—a major problem for him throughout his transplant course.
The severe degree of narrowing and hyalinization of arterioles
observed in the transplant biopsy specimen are consistent with the
pathologic changes observed in hypertensive nephrosclerosis. A
significant negative correlation has been demonstrated between
renal allograft survival and the presence of hypertension [47].
Furthermore, in patients with chronic rejection, the severity of
histologic change as well as the rate of deterioration in renal
function correlates with the degree of hypertension [14, 48].
Taken together with the documented importance of systemic
hypertension in the development of renal damage in native
kidneys [49, 50], these findings suggest that hypertension contrib-
utes significantly to renal allograft injury.
Hypertension, occurring in more than 50% of renal transplant
recipients, is often multifactorial in origin, with both cyclosporine
and prednisone contributing to its development [51]. The patho-
physiology of cyclosporine-induced hypertension involves a sodi-
um-dependent mechanism as well as both systemic and renal
vasoconstriction [51, 52]. If hypertension were an important cause
of renal allograft injury, one would expect adequate blood pres-
sure control to limit deterioration in graft function. Unfortu-
nately, few studies have addressed this important question by
comparing the efficacy of various antihypertensive agents or
regimens in this setting. Calcium-channel blockers have emerged
as the agents of choice for treatment of post-transplant hyperten-
sion because they also ameliorate cyclosporine-associated neph-
rotoxicity [51, 52].
Angiotensin-converting-enzyme inhibitors (ACEI5) are partic-
ularly helpful in treating hypertension in patients with renal
disease because they lower both intraglomerular and systemic
pressure [30, 53]. Use of these agents in patients with renal
disease, especially those with diabetic nephropathy, reduces pro-
teinuria and can delay progression toward end-stage renal disease
[54]. These agents might seem ideal in the renal transplant setting
in which glomerular hypertension is present [34, 35]. Indeed,
utilizing a rat model of chronic rejection, Paul found that treat-
ment of hypertension decreased glomerular hypertension in asso-
ciation with a diminution in proteinuria and glomerular damage,
and that this effect was most pronounced with the use of an ACEI
[55]. Use of these agents has been avoided in many transplant
centers because physicians fear that these drugs are nephrotoxic
when used with cyclosporine. To date, only a handful of studies
have examined the effect of ACEIs on post-transplant proteinuria
or on preservation of renal function. In three short-term clinical
trials in hypertensive renal transplant patients with proteinuria,
ACEIs ameliorated hypertension and decreased proteinuria [56—
58]. In contrast, Mourad et al were unable to demonstrate any
benefit of lisinopril on urinary albumin excretion in hypertensive
renal transplant patients after 2.5 years of followup [591.
One must be cautious when using ACEIs simultaneously with
cyclosporine because a reduction in GFR is often observed in this
setting [57, 60]. Although lowered GFR might be of little clinical
significance in patients with reasonable graft function (GFR  50
mi/mm) [57], acute renal failure can occur with the use of ACEIs
in cyclosporine-treated renal transplant patients, even in the
absence of renal artery stenosis [61]. Rell et a! observed acceler-
ated deterioration in renal function in 5 of 22 transplant patients
with reduced creatinine clearance who were given enalapril to
decrease proteinuria [581. This phenomenon is likely explained by
efferent arteriolar relaxation in the setting of cyclosporine-in-
duced afferent vasoconstriction.
Renal ischemic injury. Today's patient required dialysis for 10
days because of delayed graft function (DGF). Delayed graft
function due to renal ischemic injury occurs in 25% to 50% of
cadaveric transplant recipients and can be exacerbated by cyclo-
sporine [62, 63]. Recipients with DGF experience a significant
decrease in long-term graft survival, especially if dialysis is re-
quired for more than one week [64—66, 67].
Additional data supporting the adverse effect of renal ischemic
injury on long-term graft survival are derived from results ob-
tained in recipients of living unrelated transplants. Graft survival
in these recipients, for whom cold ischemia time is minimal, is
superior to that observed in recipients of cadaveric grafts despite
a similar degree of HLA mismatch [44].
Delayed graft function could contribute to a shortened graft
survival via immunologic as well as nonimmunologic mechanisms.
Yilmaz et a! have demonstrated that the pathologic changes
observed in a rat model of chronic rejection are worsened by
ischemic injury at the time of transplantation [68]. The frequency
of acute rejection is also higher in patients with DGF [64, 69]. This
might be due to the increased difficulty in detecting rejection in
patients with DGF but also might be explained by recent evidence
demonstrating that ischemia enhances class-Il antigen expression
on renal endothelial cells, thus making the kidney more antigenic
[701. Although it has been postulated that this higher frequency of
rejection is the major reason for decreased graft survival in
patients with DGF [691, registry data clearly demonstrate a
tendency toward reduced allograft survival with DGF even for
patients who do not experience an acute rejection episode [67].
These data thus support the concept that nonimmunologic mech-
anisms also might partly explain the adverse effect of ischemic
damage on long-term graft survival. Maneuvers that decrease the
occurrence or severity of DGF improve long-term graft survival
[71—731.
Drug toxicity. The extensive interstitial fibrosis observed in
today's patient's renal biopsy also could be explained by chronic
cyclosporine nephrotoxicity [74], because the interstitial changes
of chronic rejection and chronic cyclosporine nephrotoxicity often
are indistinguishable [75, 76]. The mechanisms by which cyclospo-
rine induces interstitial fibrosis involve both ischemic damage
from chronic vasoconstriction as well as direct effects promoting
interstitial matrix formation [77]. But in contrast to the original
report by Myers, in which he described a chronic progressive
nephropathy in heart transplant patients treated with cyclosporine
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[74], more recent results using lower doses of cyclosporine
indicate that the drug causes an initial but not progressive
decrease in GFR. Renal function has remained stable for 6 to 8
years in renal transplant patients maintained on cyclosporine [78,
79]. It might be incorrect to conclude, however, that cyclosporine
has no adverse effect on long-term renal allograft function merely
because of the absence of documented progressive nephropathy
associated with its use to date. It is still possible that the initial
cyclosporine-induced decrement in GFR or the later development
of interstitial fibrosis adds a hemodynamic stress on the remaining
nephrons, which subsequently contributes to long-term renal
compromise, especially in patients with pre-existing renal injury
from ischemia or rejection. Why has the frequency of chronic
rejection remained unchanged with the use of cyclosporine de-
spite the drug's proven ability to decrease both the frequency and
severity of acute rejection? Perhaps our failure to observe an
improvement in long-term allograft survival with this drug, despite
its superiority as an immunosuppressive agent, is partly due to the
renal hemodynamic sequelae associated with its use.
The use of very low doses of cyclosporine to avoid this problem
is ill advised. Several studies have demonstrated an increased
frequency of both late acute rejection [80] and chronic rejection
[19] when cyclosporine doses are too low. For these reasons,
current recommended doses for optimal maintenance remain
between 4—5 mg/kg/day [81]. Although chronic cyclosporine neph-
rotoxicity likely contributed to the renal lesion in the patient we
are discussing today, his nephrotic-range proteinuria, which is not
a feature of cyclosporine toxicity, suggests that other factors also
were important.
Hyperlipidemia. Hyperlipidemia was present in this patient, as it
is in as many as 30% of renal transplant recipients [82, 83].
Elevated LDL cholesterol is the most common pattern observed,
although hypertriglyceridemia also is seen. Hypercholesterolemia
worsens renal damage in several experimental models of renal
injury [84—86]. Because the vascular changes of chronic rejection
resemble the early arteriosclerotic lesion, several investigators
have postulated that excess lipids also play a role in the develop-
ment or exacerbation of this process [21—23]. When elevated
levels of LDL coexist with inflammation, as in chronic rejection,
oxidatively modified LDL can be produced locally. This reactive
LDL produces a number of effects that enhance the patient's
immune response, such as an upregulation in class-Il antigen
expression, impairment in nitric oxide synthesis, and exacerbation
of endothelial cell damage [21—23, 87]. Vascular lesions resem-
bling chronic rejection can be worsened by high cholesterol and
triglyceride feeding in experimental models of chronic vascular
rejection [22].
A higher frequency of hyperlipidemia has been observed in
some [87] but not all [16] patients with chronic renal allograft
rejection. It is difficult to judge from these retrospective studies
whether the hyperlipidemia is causal or results from the nephrotic
syndrome and renal insufficiency that usually accompany chronic
rejection. Nonetheless, Dimeny et al found a significant increase
in vascular intimal hyperplasia on renal biopsy at 6 months after
transplantation in patients with pre-transplant hypercholesterol-
emia [87]; the data thus suggest that hyperlipidemia is a risk
factor. To date no clinical studies have assessed the ability of
lipid-lowering drugs to prevent or delay the course of chronic
rejection.
Conclusions. To summarize, in a patient with chronic allograft
nephropathy, the pathologic changes and loss of renal function
could involve a number of factors in addition to an alloimmune
response to foreign antigens. It is likely that no single factor is of
sole importance but rather that several factors interact with each
other and with immunologic events to worsen renal damage (Fig.
3). In today's patient, the combination of damage from acute
rejection, ischemic injury, hypertension, and drug toxicity could
have reduced his functional nephron mass to the critical level at
which the sequelae of glomerular hypertension are observed. This
scenario would have been even more pronounced if an insufficient
"nephron dose" had been utilized originally. His hyperlipidemia
also would have been important if it had potentiated the vascular
damage associated with chronic rejection. If we accept these
factors' potential to promote renal injury in native kidneys, it
makes sense for us to suspect that they might play a role in the
transplant setting as well.
The potential for the prevention or treatment of the nonimmu-
nologic factors responsible for renal allograft injury underscores
the need for confirmation of their contribution to the lesion.
Table 4 lists areas of investigation that could help us clarify the
importance of these factors. Experimental studies comparing
long-term graft survival in recipients of one versus two allografts
would be an ideal way of examining the importance of "nephron
dosing." Clinical data pertaining to this concept also should be
Hyperlipidemia Pathologic changes of
chronic allograft
nephropathy
Chronic
immunologic
reaction
—a- Vascular-.-
injury
N
I
Inadequate nephron mass
Fig. 3. Schema depicting interaction of
nonimmunologic factors with each other and with
immunologic factors to produce the pathologic
changes observed in patients with chronic
rejection (now called "chronic allograft
nephropathy").
Nephrology Forum: Nonimmunologic causes of late renal graft loss 1475
Table 4. Proposals for future areas of investigation
Nephron dosing Experimental studies to confirm the
importance of nephron dosing
Enter donor kidney weight into
registry data
Hemodynamic factors Use of low-protein diet
Use of angiotensin-converting-enzyme
inhibitors
Delayed graft function Prevention with calcium-channel
Hypertension
blockers or other protocols
Determine the best treatment
Hyperlipidemia Determine the value of treatment
generated by measuring kidney weights at the time of transplan-
tation—a step not routinely done currently. If this parameter were
entered into the transplant registry data base, analysis of the
impact of donor kidney weight/recipient weight on long-term graft
survival could be examined readily. Although it is premature to
recommend that recipients receive two instead of one kidney
[251—especially in this era of a relative dearth of transplantable
kidneys—we should be more cognizant of the concept of
"nephron dosing" and derive data to support or negate its
importance in long-term renal allograft survival.
Studies also should address the value of protein restriction and
the use of ACEIs in slowing progression toward ESRD in patients
with chronic rejection. Two studies involving a total of 14 patients
with chronic rejection have demonstrated that protein restriction
either decreased urinary protein excretion [26] or improved the
slope of the reciprocal of the serum creatinine with time [88].
With the potential dangers of inducing a negative nitrogen
balance from protein restriction in patients taking steroids or
producing nephrotoxicity due to the concomitant use of ACEIs
and cyclosporine, these practices should be examined in clinical
trials before being recommended in all patients with chronic
rejection, that is, chronic allograft nephropathy.
We should continue to explore protocols designed to reduce
renal ischemic damage at the time of transplantation. Greater
consideration should be given to the routine use of calcium-
channel blockers in the pen-transplant setting. Both we [89] and
others [90] have demonstrated that these agents ameliorate
cyclosporine-induced exacerbation of renal ischemic injury in
animal models, and this finding has been confirmed in several
clinical studies [71, 72, 91, 92]. The beneficial effect is most
pronounced when the agents are injected into the donor kidney
and given immediately to the recipient [72, 91, 921. Although
calcium-channel blockers are used frequently in transplant pa-
tients, they often are not administered until a few days to weeks
post transplantation. I suggest that greater consideration be given
to their earlier utilization because of their potential benefits and
generally low toxicity.
Last, we need to establish whether aggressive treatment of
hypertension and hyperlipidemia affects long-term allograft sur-
vival. Since these two factors have been identified as risk factors
for cardiovascular events in renal transplant patients [93, 94],
aggressive treatment potentially could improve patient survival as
well. Prospective studies comparing the efficacy, cost, and side
effects of different hypertensive regimens would be helpful. The
potential of lipid-lowering agents to prevent cardiovascular dis-
ease or chronic rejection in this population also should be
confirmed before we prescribe even more drugs, which drive up
cost and undoubtedly contribute to noncompliance.
Significant attention is now being focused on the potential
immunologic mechanisms involved in chronic rejection [10—12,
21—23]. I strongly believe that it is equally important to direct
investigative attention to the nonimmunologic factors that could
contribute to renal allograft injury. Studies are needed to define
the significance of these factors and to determine whether their
prevention or treatment can prolong renal allograft survival.
Questions and answers
DR. JOHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): Dr. Bia,
given the information that you presented about the problems of
cyclosporine, shouldn't there be a rigorously controlled study of
the cessation of cyclosporine after 1 to 2 years? I realize that there
have been several studies, but in most of them, the cyclosporine
was abruptly stopped. Perhaps it should be tapered over 6 to 9
months. Would you comment on this?
DR. BIA: In many of the original studies examining cyclosporine
conversion, the drug was discontinued abruptly within the first 4 to
6 months post transplant. However, in more recent studies, the
drug has not been discontinued until after the first year and it has
been tapered slowly over 6 weeks to 8 months [79, 95]. Despite
these precautions, a frequency of acute rejection of approximately
30% has been observed consistently. Because acute rejection is
likely to be the most important factor that influences the occur-
rence of chronic rejection, the late occurrence of acute rejection
is probably something we should avoid as much as possible. A
meta-analysis of 17 studies of cyclosporine withdrawal has dem-
onstrated a significant increase in the rate of acute rejection in
patients withdrawn from cyclosporine compared to those who
remained on the drug [96]. In this evaluation, none of the
outcomes was affected by the timing or manner of cyclosporine
withdrawal.
DR. HARRINGTON: Given that information, can you predict
which patients can discontinue the cyclosporine? Can we identify
the 70% or so of patients who do not need the cyclosporine?
DR. BIA: No, and that is the problem. While factors such as
African-American race, a high degree of reactivity, and previous
rejection predict rejection after cyclosponine cessation [81, 95], we
still cannot identify the majority of the patients who will experi-
ence such a rejection.
Da. I-IARRINGT0N: You talked about the potential ill effects of a
mismatch between donor and recipient age. Would you elucidate
this issue? What are the facts regarding outcome in children
receiving adult kidneys, usually a parent donating to a child? Is
this issue resolved by the Roth data [42]?
DR. BIA: Renal allograft survival in children is actually slightly
lower than in adults, although this point is still somewhat contro-
versial. Reasons for these results include both technical difficulties
as well as the presence of a more robust immune system in
children [97]. When donor age has been examined, kidneys from
very young donors (<6 years old) pose the greatest risk for
pediatric recipients [97]. I have not seen similar analyses for
children receiving kidneys from older donors. Patients in the Roth
study were adults with a mean age of 44 10. These statistics
might be improving due to better immunosuppression and better
organ allocation policies for children [97].
DR. PAUL BERNSTEIN (Postdoctoral Fellow, Yale University
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School of Medicine, New Haven, Connecticut): Dr. Bia, we con-
stantly invoke cyclosporine-induced vasoconstriction as the possi-
ble cause for nonimmunologic injury. Are there any markers,
either in animal models or in human transplant patients, for
vasoconstriction or vasodilation? That is, have prostacycline or
thromboxane levels been looked at in the urine to see whether we
are, in fact, vasoconstricting the transplanted kidney?
DR. BIA: Yes, ample evidence, both in experimental animals
and in humans, demonstrates that cyclosporine alters eicosanoid
balance, inhibiting prostacycline synthesis, and enhancing throm-
boxane production. Endothelin synthesis also is stimulated by
cyclosporine, and transient increases in urinary endothelin levels
have been observed in renal transplant patients in the first 6 hours
after their daily cyclosporine dose [98].
Renal vasoconstriction also can be explained by an increase in
sympathetic tone, as the effect can be blocked by phenoxyben-
zamine in rats [99]. Increased sympathetic tone has been docu-
mented in cyclosporine-treated cardiac transplant patients, but
the effect might be less important in renal transplant patients
whose kidneys are denervated.
DR. GJACOMO BASADONNA (Associate Professor of Surgery, Yale
University School of Medicine): Do you think that the cyclosporine
effect is more likely due to the high dose in the beginning, when
the kidneys are more fragile and sensitive, or do you think it's
more of a long-term problem?
DR. BIA: That's a very interesting question. There is no doubt
that the acute vasoconstrictive effect of cyclosporine is related to
high levels and often can be ameliorated by a reduction in dosage.
It is unknown, however, whether the use of very high doses of
cyclosporine initially post transplant, especially in ischemic kid-
neys, leads to permanent nephron loss with an increased burden
of hyperfiltration in the remaining nephrons. If this were true, the
use of high doses of cyclosporine initially would contribute to a
shortened graft survival. Alternatively, graft survival could be
compromised by the interstitial fibrosis that develops over time on
even modest cyclosporine doses (5—10 mg/kg/day). Much of these
data have been generated in nonrenal transplant patients and
patients with autoimmune diseases. In a recent report of cardiac
transplant recipients started on a moderate, not high, dose of
cyclosporine (8 mg/kg/day), significant loss of renal function
(creatinine >250 mmol/liter) was seen in 4 years in 13% of
patients, with 6 of 202 patients developing end-stage renal disease
[100]. These results suggest that long-term exposure to cyclospo-
rine, even at modest doses, has a long-term detrimental effect on
renal function in some patients.
DR. JOHN HAYSLEYF (Professor of Medicine, Yale University
School of Medicine): Peggy, I have difficulty understanding the
concept of nephron dosing, that is, the notion that renal fibrosis is
more likely to occur under conditions when metabolic demands
placed on the kidney exceed some limit. Although the notion that
patients with morbid obesity have a higher incidence of focal
glomeruloscierosis is popular, we have no scientific evidence to
prove that correlation. In normal human development, previous
studies have shown that filtration rate correlates with metabolic
rate, reflected by body surface area. I know of no evidence that the
larger adaptive changes per nephron that occur in large people,
compared to small individuals, are associated with a pathologic
corollary. I would expect that a previously healthy grafted kidney
would adapt to the size of a new host, as it did to the former host.
In regard to the question of whether a mismatch between the
body size, and therefore kidney size, between donor and graft
recipient is an important factor in graft survival, it might be useful
to estimate graft function in relation to surface area to determine
whether smaller grafted kidneys fail to adapt appropriately as
compared to larger kidneys.
DR. BIA: John, you are absolutely correct in suggesting that we
need better markers of nephron number and filtration surface
area. Until such methods become available, however, we are left
with a less accurate but more practical measurement, such as
donor kidney weight or kidney size, to reflect nephron number.
Despite the potential inaccuracy of kidney weight as a reflection
of nephron number, using data comparing donor kidney weight/
recipient body weight with graft outcome might turn out to be an
important and easy method for avoiding the most severe donor-
recipient mismatches.
With regard to your question about the lack of renal pathology
in obese subjects, the outcome might be a matter of original
nephron number. That is, hyperfiltration due to a large metabolic
demand might not result in renal insufficiency when one starts
with the large number of nephrons present in two native kidneys.
Such hyperfiltration could, however, compromise graft function in
a transplant patient who starts with a reduced nephron number
due to a single kidney and develops additional damage from
ischemia or rejection.
DR. PAUL DOOLAN (Clinical Professor of Medicine, Yale Univer-
sity School of Medicine): Some of us take issue with the cavalier
notion of correlations of organ sizes. If you are going to use a
reference, you're probably going to use a reference based on lean
body mass. If you want to treat the kidney as one organ and cite
gross renal weight as your reference point, you are free to do so,
but appreciate the fact that that approach may be inaccurate. It is
well known that tremendous heterogeneity exists in the nephron
population, which affects the progression of renal disease. As the
painstaking studies of Jean Oliver have demonstrated, the kidney
contains agglomerular nephrons, small glomeruli, and big glomer-
uli [101]. I think it is an oversimplification to talk about a dose or
monomorphic response based on hyperfiltration.
DR. BIA: Paul, your point is well taken. However, despite the
lack of precision, comparing donor kidney weight in relationship
to recipient weight to see whether gross mismatching is an
independent risk factor for shortened graft survival is an impor-
tant first step for determining the importance of so-called
nephron dosing in renal transplantation.
DR. FRED FINKELSTEIN (Clinical Professor of Medicine, Yale
University School of Medicine): I have two questions. First, can you
briefly summarize the hemodynamic effects of FKSO6 compared
with cyclosporine? Second, I'd like to return to Dr. Harrington's
initial question, which struck me as very important. Have any
centers been performing in-vitro immunologic testing of recipi-
ents' lymphocyte reactivity to donor antigens as a way of deter-
mining the patients in whom one could reduce the dose of
cyclosporine or switch from cyclosporine to azathioprine?
DR. BrA: Published data indicate that FK506 has the same
nephrotoxicity profile as does cyclosporine [102]. Both drugs
lower renal blood flow and increase renal vascular resistance.
Similar pathologic findings in the renal interstitium and vascula-
ture also have been described [103]. In clinical trials to date, the
frequency and severity of renal insufficiency with FK506 seem to
be similar to those of cyclosporine [104], although more work is
needed to confirm these observations.
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Regarding your question about immune testing, the transplant
community continues to await an immunologic test that will
accurately reflect a patient's level of immunosuppression or
tolerance to donor-specific antigens. The tests that do exist are
either too cumbersome or too inaccurate for routine clinical
decision-making.
DR. MICHAEL KASHGARIAN (Professor of Pathology and Biology,
Yale University School of Medicine): Are there differences in the
rate of progression of graft failure that can be related to either the
degree of hypertension, the degree of hyperlipidemia, or the
number of acute rejection episodes? Can we separate out which of
these multifactoral processes are most or least important in graft
failure in the long run?
DR. BIA: You ask an extremely important question that needs
to be addressed. In the few published studies in which risk factors
for chronic rejection have been examined, acute rejection has
been determined to be an important factor [17, 18]. In addition, as
I said earlier, the progression of renal insufficiency in patients with
chronic rejection correlates with the degree of hypertension [14,
48]. To my knowledge, no one has examined all of the nonimmu-
nologic factors together to determine their relative importance.
Obviously, this is something we need to do. It is important to note,
however, that retrospective studies examining the frequency of
these nonimmunologic factors in patients with chronic rejection
might not be the best method of determining their role in the
process, because several of these factors, such as hypertension and
hyperlipidemia, can occur as a result of chronic rejection.
DR. HARRINGTON: Dr. Bia, you mentioned that Yale is begin-
ning to use living unrelated donors, just as many other facilities
are doing. What criteria do you use for that choice, given the
information you told us about nephron dosing today?
DR. BIA: We try to evaluate all living related and unrelated
donors to make sure that no undue pressure is being exerted on
them to donate. This psychosocial evaluation is performed by our
transplant social worker and by the transplant nurse coordinators.
In our experience, most of these donors have been spouses, living
mates, or close friends of the recipient. We have not yet taken
donor and recipient size into account but, as I said, I think we
should at least start collecting the data on this issue. In a recent
study we just completed as part of an American Society of
Transplant Physicians survey on donor workup, only 8 of 173
transplant centers in the US (5%) reject an adult donor consid-
ered to be too small in relation to the size of the recipient in order
to avoid future hyperfiltration. I expect the percentage of centers
doing this will increase.
MR. PETER JUERGENSON (Physician's Assistant, Yale University
School of Medicine): I have two questions about transplants from
pediatric donors (children less than 6 years of age) into adult
patients. Are there any data on protein restriction in the adult
recipient and whether it has an impact on allograft survival?
Second, is any information available suggesting that adult hor-
mone levels (that is, lack of growth hormone or possibly high
insulin levels) affect renal growth or survival?
DR. BIA: Only two published studies have examined the results
of protein restriction in renal transplant recipients [26, 88]. In
neither of these studies was the age or the size of the donor
mentioned.
There seems to be no problem with pediatric donor kidneys
responding to growth factors, as these little organs can increase 2
to 4 times their original size. The question is, what is the price for
this growth long term? Is there excessive hyperfiltration or
hypertrophy as a result of this adaptive increase in size?
DR. DAVID ELLISON (Associate Professor of Medicine, Yale
University School of Medicine, and Chief Renal Section, Veteran s
Administration Hospital, West Haven, Connecticut): You presented
some convincing data suggesting that a variety of factors affect
renal graft half-life. It seems to me, however, that most of those
factors are best viewed as accelerators of graft loss rather than as
causes. The difference in half-life between kidneys with excellent
and poor HLA matching, and the fact that transplants from
identical twins can often be maintained without immunosuppres-
sion for indefinite periods of time, suggests to me that if we had a
perfect immunosuppressive drug that made every transplant like
that between identical twins, the factors you discuss, except
perhaps cyclosporine, would not be important. Do you agree?
DR. BIA: Your point is well taken. As Figure 3 shows, chronic
allograft nephropathy or chronic rejection is definitely a response
to immunologic injury. The value of emphasizing the nonimmu-
nologic factors that can accelerate renal injury or exacerbate the
immune response to injury lies in their potential for reversibility
or prevention. In the renal transplant world, most of the efforts at
prolonging renal allograft survival have focused on advances in
immunology; clearly, these immunologic investigations are impor-
tant. Little emphasis has been placed on nonimmunologic factors,
which can contribute to renal damage and compromise long-term
survival, in contrast to the attention paid to these factors in
native-kidney renal insufficiency. My point is that because these
factors are likely important in the transplanted kidney as well, it is
time for us to focus efforts on verifying this hypothesis and
determining whether better control or prevention of these factors
will result in a prolongation of renal allograft survival.
DR. HARRINUTON: Cyclosporine nephrotoxicity in part seems to
be related to the generation of extracellular matrix. Has anyone
done studies to show that blockers of TGF/3 affect the production
of extracellular matrix in vitro or in vivo?
DR. BIA: Yes, work in the laboratory of Wayne Border has
elegantly demonstrated that TGFI3 plays a pivotal role in the
pathologic accumulation of extracellular matrix in experimental
models of glomerulonephritis and that this effect can be sup-
pressed with administration of anti-serum to TGFI3 [1051.
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